SURVYR

NEO

NeoGenomics, Inc.
$17.27
+$0.58 (3.48%)Oct 27 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-30%+2%+34%+66%+98%Oct 2025Oct 2026Apr 202652w high $20.1552w low $7.07
NEOSPY
Wall St. Highest PT $35.00 (+102.7%) Wall St. Avg PT $21.85 (+26.5%)
$7$14$22$29$36POC $12Hi $35Avg $22
Underwater Drawdown %Max DD -45.6%Current -13.3%
0.0%-45.6%
Relative Strength vs SPY+56.4% vs SPYOutperforming
+96%0%-96%
1W
+$0.65 (3.91%)
1M
−$2.06 (10.66%)
3M
+$3.87 (28.88%)
6M
+$8.25 (91.46%)
YTD
+$5.51 (46.85%)
1Y
+$7.11 (69.98%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
12 analysts · mean score 1.67
1 = Strong Buy · 5 = Sell
Strong Buy758%
Buy217%
Hold325%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 13, 2026
Analyst price targets
Current price$17.27
Average target$21.85
+$4.58 (+26.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$16.50
Median$20.00
High$35.00
12-month Wall Street target range · as of Oct 13, 2026
Recent analyst rating changes · 30
Reiterated
2026-10-06 · StoneX reiterated Buy on NEO
Reiterated
2026-10-06 · Needham reiterated Buy on NEO
Upgrade
2026-10-06 · BTIG upgraded NEO from Neutral to Buy
Reiterated
2026-07-29 · Needham reiterated Buy on NEO
Reiterated
2026-07-24 · Benchmark reiterated Buy on NEO
Upgrade
2026-04-29 · Benchmark upgraded NEO from Hold to Buy
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Grey zone
Altman Z-score 2.5
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Average
Piotroski F-score 4 of 9
See the tests
  • ✗Positive net income
  • ✓Positive operating cash flow
  • ✗Return on assets improved
  • ✓Cash flow above net income
  • ✗Long-term debt / assets fell
  • ✓Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$2.2B
P/E (next 12 months, estimated)50.4
52-week range$7.07 – $20.15
Revenue growth (latest quarter vs a year ago)+11.2%
Dividend yieldNo dividend
Analyst consensusBuy (10)
Average analyst price target$21.85 (+27%)

What they do

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▼Forward P/E vs sector50.4x vs median 18.0x
•Piotroski F-score4/9
•Altman Z2.5 (grey)
▲Analyst target+27% (10 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.78 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 31.2×
 –
Forward P/E
sector median 18.0× · 95th pct
 50.4×
pricier
EV / EBITDA
sector median 16.2×
 –
Price / sales
sector median 3.3× · 46th pct
 2.9×
cheaper
Price / book
sector median 3.5× · 39th pct
 2.8×
cheaper
FCF yield
sector median 4.0% · 10th pct
 -0.3%
pricier

Forward EPS $0.34 vs trailing $-0.39. Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO
$267.0M
as of 2021-12-31
vs a year ago
+28%
YoY
× TTM revenue
0.35×
coverage
18-03
18-06
18-09
18-12
19-12
20-12
21-12

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin
43.9%
Operating margin
-8.9%
FCF margin
-1.0%
Net margin
-6.8%
Return on equity
-6.6%
Return on invested capital
-6.5%
Net debt / EBITDA
–
Current ratio
3.6×
Interest cover
-26.5×
Cash conversion (OCF/NI)
–
Piotroski F-score 4/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 2.5 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$22
+27%
Analysts
10
Buy
Range
$16–$35
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$727.3M$-108.0M$-21.8M
2024$660.6M$-78.7M$-34.0M
2023$591.6M$-88.0M$-30.7M
2022$509.7M$-144.2M$-96.9M
2021$484.3M$-8.3M$-90.9M
2020$444.4M$4.2M$-27.6M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +12.6%.

For information only · Important disclosures

Grades vs sector

Momentum
95th percentile in sector
A+
12-1 return: +87.9%
Percentile within its GICS sector across the S&P 1500.
Growth
64th percentile in sector
B-
Revenue growth (YoY): +11.2%
Percentile within its GICS sector across the S&P 1500.
Value
4th percentile in sector
F
Forward E/P: 2.1% · EBITDA/EV: 1.0%
Percentile within its GICS sector across the S&P 1500.
Profitability
15th percentile in sector
D-
Profit margin: -6.8% · Return on equity: -6.3%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Held by 1 of 7 live models: Momentum Blend.

Momentum Blend
5.4% of the book · Leaders sleeve
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the Momentum Blend

In the Leaders sleeve: a fast grower breaking out near its highs after an earnings-style gap.

What would knock it out: Exits if it closes below its stop of $14.56; last close $17.27, 19% above it.

Earnings & events

NEO earningsReports today
Next report · quarter Sep 2026
Wed Oct 28, 2026After the close
EPS consensus$0.06 range $0.04–$0.07
Revenue consensus$207.3M 11 analysts
Last 4 quarters · EPS vs estimate
Jul 28, 2026$0.05est $0.03+48.6%Above estimates
Apr 28, 2026$0.01est –+800.9%
Feb 17, 2026$0.06est $0.04+50.0%Above estimates
Oct 28, 2025$0.03est $0.02+25.8%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:03:48 ET
24-0724-1125-0225-0725-1026-0226-0426-070.000.06
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$201.7M+11.2%
2026-03-31$186.7M–
2025-12-31$190.2M–
2025-09-30$187.8M–
2025-06-30$181.3M–

News & catalysts

More news
NEO reports earnings tomorrow, after the close
Nasdaq earnings calendar · 9h ago
IBD Stock Of The Day, Natera, Hovering Near Buy Point
Investor's Business Daily · Oct 22

Research

Momentum Blend: rebalance of Sep 30, 2026Oct 22, 2026
Rating changes
Reiterated
2026-10-06 · StoneX reiterated Buy on NEO
Reiterated
2026-10-06 · Needham reiterated Buy on NEO
Upgrade
2026-10-06 · BTIG upgraded NEO from Neutral to Buy
Reiterated
2026-07-29 · Needham reiterated Buy on NEO
Reiterated
2026-07-24 · Benchmark reiterated Buy on NEO
Upgrade
2026-04-29 · Benchmark upgraded NEO from Hold to Buy

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Aunan Greg D
Chief Accounting Officer · 2026-08-04
Sell
$321.4K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:03:48 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026